POPESCU IULIAN PhD, MD, Clinical Department of Radio-Biology at the Fundeni Clinical Institute in Bucharest
e-mail: popdociul@yahoo.com
ALINA HALPERN PhD, SF.ŞTEFAN Hospital Bucharest
INTRODUCTION
Study of the molecular pathology of lung cancer (LC) has contributed
and is further contributing to a more
deepened knowledge of pre-neoplastic lesions, of carcinogenesis
process, of metastatic invasion and
disseminations. By simultaneously
highlighting multiple markers the early diagnosis
becomes possible in the targeted treatment of
LC. So far the LC
treatment was a uniform treatment
for a heterogeneous disease. These cumulated data give hope for the
increase of survival rate, which
currently is one of the lowest